IVG-PREMIUM-E-LIQUIDS
IVG Premium E-Liquids, the UK’s market-leading brand, has announced a strategic partnership with globally renowned Kollaras & Co – A 3rd generation, family owned and operated business. Kollaras & Co specialises in supporting independent retailers across multiple channels in Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005029/en/
Kollaras & Co have landed the master distribution rights for IVG products within Australia, which will allow vapers from down under to join vapers from over 60 countries and 6 continents that vape premium British flavours from IVG.
John Kollaras, Managing Director of Kollaras & Co, commented that the alliance was an important step for the near 60-year-old business, commenting “We are thrilled to partner with IVG, as we continue to strive to provide a unique offering within our portfolio, and cement our position as a dynamic solutions provider.” Kollaras continued: “Quality, authenticity and passion are three key values which we look for in partners, and IVG is no exception to this.”
Ahsan Bawa, CEO of IVG, commented that “Our incredible journey continues here at IVG, our multi international and award winning brand continues to reach new heights. We are proud and honoured to welcome the Kollaras family into our own, and this strategic alliance will help in those efforts on delivering IVG to a store near you. We are thrilled to officially announce the partnership with Kolloras & Co, a key step for Oceania & South Pacific regions
Kollaras & Co will be distributing 26 delicious e-liquid flavours in 60 ML and 10 ML from IVG Premium E-Liquids’ into the Australia retail market sector by the end of April 2019.
13 International Accolades “Leading E-Liquids Specialist 2019”, Best Sweet Flavour, and more have played a key role in the Australia company taking the products on board, along with the existing reviews of the vape enthusiasts in the Australian market.
Kollaras closed by adding “Our core innovation metrics focus on creating brands that are valued by our customers and deliver outstanding value to their shoppers, and IVG is a fantastic example of this. We are both confident and excited about the partnership and our growth prospects in the year ahead to say the least!”
About IVG Premium E-Liquids - www.ivgeliquids.co.uk
About Kollaras & Co: www.kollaras.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005029/en/
Contact:
Media Contact: Deepika Patel Head of Marketing +44 (0) 1772 217000 deepika.patel@ivgeliquids.com
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release
ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom